Common Stock, par value $0.0001 per share
- Symbol
- FRNM
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.01, 9.01 · 8-K/A
Freenome, Inc.
FRNMNASDAQEQUITYCurrent
Completion of Acquisition or Disposition of Assets
Item 2.01. Completion of Acquisition or Disposition of Assets Financial Information Management’s Discussion and Analysis of Financial Condition and Results of Operations of Freenome for the three and six months ended June 30, 2026 and 2025 is set forth in Exhibit 99.2 to this Amendment No. 1, and is incorporated herein by reference.…
Company context
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com.
Current securities
Historical securities (1)
Registered securities in this filing
FREENOME, INC. · 8-K/A · Filed 2026-08-13
Disclosure sections
Item 2.01Item 2.01 - Completion of Acquisition
Item 2.01. Completion of Acquisition or Disposition of Assets
Financial Information
Management’s Discussion and Analysis of Financial Condition and Results of Operations of Freenome for the three and six months ended June 30, 2026
and 2025 is set forth in Exhibit 99.2 to this Amendment No. 1, and is incorporated herein by reference.
Quantitative and Qualitative Disclosures about Market Risk
As a “smaller reporting company,” New Freenome is not required to provide this information.
Filed exhibits (2)
EX-99.1 2 ef20080133_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FREENOME HOLDINGS, INC. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except shares and par value data) June 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 85,467 $ 78,558 Marketable securities 16,557 138,106 Accounts and oth…
Open exhibit ↗EX-99.2 3 ef20080133_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of the financial condition and results of operations of Freenome Inc. (“New Freenome,”, “we,” “us,” and “our”) should be read in conjunction with our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026 and 2025, and the audited consolidated financial statements as of and for the year ended December 31, 2025, and in each case, together with the related notes thereto, included elsewhere in this Current Report on Form 8-K with respect to the unaudited condensed consolidated financial statements or included in the proxy statement/prospectus filed with the SEC on June 17, 2026 incorporated herein by reference with respect to the audited consolidated financial statements only. The discussion and analysis should also be read together with the pro forma financial information included in this Current Report on Form 8-K in the section titled “Unaudited Pro Forma Condensed Combined Financial Information.” Forward-Looking Statements This …
Open exhibit ↗